Medidata has become the latest trial tech firm to team with speech collection and analysis software developer Aural Analytics to add speech biomarkers to its drug research offering.
The partnership—financial terms of which were not provided—will integrate Aural’s Speech Vitals technology into Medidata’s cloud analytics network. The tech will be used in all studies where speech may be relevant, such as in neurodegenerative, neuropsych and other areas, an Aural spokesman told Fierce Biotech. Aural is also exploring digital biomarker development projects that Medidata may later use.
Read the full article: More than just talk: Medidata partners with speech tech firm Aural Analytics
